Peter Greenleaf - 11 May 2021 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: AUPH
Reported as of: 11 May 2021
Net transaction value: +$54,891
SEC form: 4
Accepted by SEC: 12 May 2021, 16:32:25 UTC
Next SEC filing: 14 Jun 2021
Source filing: View source filing
Reporting owner signature: /s/ Peter S. Greenleaf

Key filing fact

Peter Greenleaf filed Form 4 for Aurinia Pharmaceuticals Inc. (AUPH) on 12 May 2021.

Key facts

This page summarizes Peter Greenleaf's Form 4 filing for Aurinia Pharmaceuticals Inc. (AUPH).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 12 May 2021, 16:32.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$54,891.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AUPH transaction

Common Stock

Purchase

Transaction value: $21,650
Shares: +2,133
Change %: +26%
Price: $10.15
Shares after: 10,461
Date: 11 May 2021
Ownership: Direct
Footnotes: F1

AUPH transaction

Common Stock

Purchase

Transaction value: $33,241
Shares: +2,992
Change %: +29%
Price: $11.11
Shares after: 13,453
Date: 11 May 2021
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $9.74 to $10.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Footnote F2

The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $10.91 to $11.275, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.